Harnessing the Body’s Natural Mechanisms: Aphaia Pharma’s Novel Approach to Metabolic Disease Treatment

A Vision Rooted in Restoring Physiological Balance

Steffen Bolz’s journey with Aphaia Pharma began with a daring idea — to “cure diabetes with sugar.” Though unconventional, this concept quickly transformed into a mission focused on leveraging the gastrointestinal tract’s endogenous mechanisms.

As Bolz explained, “I co-founded the company and became the Chief Scientific Officer, and we just wanted to try to determine whether essentially you can cure diabetes with sugar.”

This shows his early motivation, highlighting the bold, unconventional thinking that laid the foundation for the company.

Aphaia Pharma’s investigational oral formulation, composed of coated glucose beads, is engineered to bypass the upper small intestine and safely reach targeted regions of the distal small intestine. When mixed with water, the beads form a gel-like matrix that delivers a controlled dose of glucose, effectively “awakening” nutrient-sensing L cells. These cells coordinate the release of a broad spectrum of enteric hormones — including GLP-1, peptide tyrosine-tyrosine (PYY), glicentin and oxyntomodulin (OXM), among others — which regulate glucose metabolism, satiety and energy expenditure.

Bolz used a “Sleeping Beauty” metaphor to illustrate this mechanism: the dormant L cells, with the appropriate stimulus — akin to a prince’s kiss — are reactivated to release their stored hormonal “orchestra.” This analogy not only clarifies the reactivation process but also highlights the advantage of utilizing the body’s natural system over high-dose, exogenous hormone replacements.

Recent company news further underscores the promise of this approach. Positive Phase II data from a prediabetes trial, demonstrating improved glucose tolerance, along with successful enrollment in the second arm of its Phase II obesity trial — which is exploring dosing strategies and circadian effects — reflect the robust momentum behind Aphaia Pharma’s R&D efforts.

The Science Behind the Innovation

Central to Aphaia Pharma’s approach is the restoration of endogenous hormone release. Unlike mono or dual agonist therapies that mimic only a fraction of the natural hormone repertoire, their strategy aims to re-establish a portfolio of metabolically active hormones. By targeting nutrient-sensing cells, the oral formulation triggers hormone release under physiological conditions, thereby potentially enhancing glucose tolerance in individuals with prediabetes and type 2 diabetes while broadly addressing metabolic dysfunction.

“What we do is we just use something that has been optimized over millions of years, and that might be the beauty of this approach,” said Bolz.

Compelling evidence from early-phase clinical studies — including a Phase II proof-of-concept trial in prediabetic patients — supports this mechanism. In these studies, the reactivation of endogenous hormone secretion via the oral formulation was linked to significant improvements in oral glucose tolerance test (OGTT) results, all while maintaining a favorable safety profile with minimal adverse events.

This precision-targeted strategy may ultimately provide a safer and more sustainable long-term therapeutic option for metabolic disorders compared to existing treatments, which are often limited in scope and burdened by considerable side effects.